清泄肺胃法治疗痤疮140例

目的：观察清泄肺胃中药治疗痤疮的疗效。方法：将140例痤疮患者按病情轻重分4级,均予清泄肺胃中药汤剂治疗,观察疗效。结果：140例中,基本痊愈81例（57．85%,显效29例（20.71％）,有效23例（16．43％）,无效8例（5-71%）,总有效率为94．29％。结论：清泄肺胃法对Ⅰ级、Ⅱ级痤疮基本痊愈率较高,也就是说痤疮分级越高,清泄肺胃法治疗效果越差。     

中药内服配合中药面膜治疗肠胃湿热型面部痤疮疗效观察

目的探讨肠胃湿热型面部痤疮的中医治疗方法。方法将98例肠胃湿热型面部痤疮患者随机分为治疗组49例、对照组49例。治疗组予中药汤剂内服,同时外用中药面膜;对照组予中药汤剂内服。结果治疗组疗效明显优于对照组。结论中药内服配合中药面膜治疗肠胃湿热型面部痤疮疗效显著。     

中药内服治疗痤疮近况

综合近十年来中医药治疗痤疮的有效方剂，分别从肺论治，从肝论治，从肾论治，从湿热瘀痰论治，取得了一定疗效。     

解毒祛痘胶囊治疗寻常痤疮的临床研究

目的：探索清热解毒、健脾化湿,祛痘养颜、调和气血类中药采用不同制剂治疗寻常痤疮的疗效。方法：采用自拟解毒祛痘汤治疗痤疮患者500例,将汤剂经特殊工艺加工制成解毒祛痘胶囊治疗痤疮患者500例,结果：治疗组有效率92．66％,对照组有效率91．80％,两组对比有效率P＞0．05。讨论：解毒祛痘胶囊可以替代解毒祛痘汤治疗痤疮。提示：解毒祛痘胶囊药量规范、服用携带方便,并可根据病情随时增减药量,特别适用于在校学生,易于临床推广。     

中药面膜联合异维A酸胶丸治疗肠胃湿热型痤疮临床研究

目的:观察自制中药面膜外敷配合异维A酸胶丸口服治疗痤疮肠胃湿热证的临床疗效。方法:81例患者随机分为治疗组和对照组,治疗组41例予中药面膜联合异维A酸胶丸治疗,对照组40例给予异维A酸胶丸与罗红霉素胶囊口服。两组均以4周为1个疗程,2疗程后比较两组的临床疗效。结果:治疗组有效率为95.12%,对照组有效率为77.50%,两组有效率比较,差异有统计学意义(P<0.05)。结论:中药面膜联合异维A酸胶丸治疗治疗肠胃湿热型痤疮有显著疗效。     

健脾消痤汤加减联合草本祛痘面膜治疗痤疮临床疗效观察

[目的]研究自拟健脾消痤汤加减联合草本祛痘面膜治疗痤疮的临床疗效.[方法]将40例患者按随机数字法分为治疗组和对照组,两组各20例,治疗组予以自拟健脾消痤汤加减治疗,并加用草本祛痘面膜敷面;对照组采用阿奇霉素联合丹参酮胶囊治疗.[结果]治疗组治愈率、有效率分别为60％、95.0％,均明显高于对照组,两者比较,差异具有统计学意义(P＜0.05).[结论]自拟健脾消痤汤加减并外敷草本祛痘面膜治疗痤疮具有满意的临床疗效.     

痤疮净配合中药面膜治疗寻常痤疮临床观察

目的:观察痤疮净配合中药面膜治疗痤疮的临床疗效.方法:86例痤疮患者,辨证分为肺经风热、湿热蕴结、痰湿凝结3型,以痤疮净加减内服配合中药面膜倒模术.结果:肺经风热型疗效最好,湿热蕴结型次之,痰湿凝结型最差,有效率为92％.结论:痤疮净合中药面膜治疗痤疮具有良好的临床疗效.     

辨证施治疗痤疮

辨证治疗青年男女痤疮,肺胃郁热型治清解肺胃活血散瘀方,脾虚湿热型治以健脾清肺汤,均取良效.     

浅析中药内服外敷、针刺治疗痤疮

本文运用中药的内服加外用的方法和针刺治疗方法治疗痤疮.     

清热除湿祛痤汤联合外用药治疗肺胃湿热型痤疮62例疗效观察

目的:观察清热除湿祛痤汤内服,联合外用0.1%他扎罗汀乳膏治疗肺胃湿热型痤疮的临床疗效。方法:123例病例随机分为两组,对照组61例予丹参酮胶囊,3次/d,维胺酯维E乳膏外用,2次/d治疗。治疗组62例予清热除湿祛痤汤,早晚各服用150 mL,外用0.1%他扎罗汀乳膏,1次/晚;连续治疗6 w。结果:对照组治疗后有效率为18.64%,治疗组治疗后有效率为43.55%,两组病例治疗后有效率比较差异有统计学意义(P<0.05)。结论:清热除湿祛痤汤内服,联合外用0.1%他扎罗汀乳膏治疗肺胃湿热型痤疮疗效显著,值得临床上推广应用。     

Treatment of Irritable Bowel Syndrome With Chinese Herbal Medicine: A Randomized Controlled Trial

Context.— Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical treatment. Objective.— To determine whether Chinese herbal medicine (CHM) is of any benefit in the treatment of IBS. Design.— Randomized, double-blind, placebo-controlled trial conducted during 1996 through 1997. Setting.— Patients were recruited through 2 teaching hospitals and 5 private practices of gastroenterologists, and received CHM in 3 Chinese herbal clinics. Patients.— A total of 116 patients who fulfilled the Rome criteria, an established standard for diagnosis of IBS. Intervention.— Patients were randomly allocated to 1 of 3 treatment groups: individualized Chinese herbal formulations (n=38), a standard Chinese herbal formulation (n=43), or placebo (n=35). Patients received 5 capsules 3 times daily for 16 weeks and were evaluated regularly by a traditional Chinese herbalist and by a gastroenterologist. Patients, gastroenterologists, and herbalists were all blinded to treatment group. Main Outcome Measures.— Change in total bowel symptom scale scores and global improvement assessed by patients and gastroenterologists and change in the degree of interference in life caused by IBS symptoms assessed by patients. Results.— Compared with patients in the placebo group, patients in the active treatment groups (standard and individualized CHM) had significant improvement in bowel symptom scores as rated by patients (P = .03) and by gastroenterologists (P = .001), and significant global improvement as rated by patients (P=.007) and by gastroenterologists (P=.002). Patients reported that treatment significantly reduced the degree of interference with life caused by IBS symptoms (P=.03). Chinese herbal formulations individually tailored to the patient proved no more effective than standard CHM treatment. On follow-up 14 weeks after completion of treatment, only the individualized CHM treatment group maintained improvement. Conclusion.— Chinese herbal formulations appear to offer improvement in symptoms for some patients with IBS.      

中药复方肠激灵治疗腹泻型肠易激综合征随机对照临床研究

【目的】综合评价中药复方肠激灵治疗腹泻型肠易激综合征(IBS-D)的临床疗效。【方法】将80例纳入研究的患者以2∶1的比例随机分为治疗组(54例)和对照组(26例)。治疗组给予肠激灵方治疗,对照组给予得舒特、黛力新治疗。2组疗程均为4周,并随访半年。评价2组临床疗效,观察2组治疗前后症状评分和生活质量量表评分变化情况。【结果】在治疗4周后,治疗组总有效率为83.33%,对照组为61.54%,治疗组疗效显著优于对照组,差异有统计学意义(P<0.05);治疗组及对照组各症状均较治疗前显著改善,差异均有统计学意义(P<0.05或P<0.01);除腹痛、情绪不安外,治疗组各症状较对照组显著改善(P<0.05)。在随访过程中,治疗组的疗效均较对照组好(P<0.05);治疗组大部分症状改善均比对照组显著(P<0.05)。生存质量方面,治疗组在治疗后及随访过程中,大部分评分与治疗前比较均有统计学意义(P<0.05或P<0.01);且大部分评分显著优于对照组,差异有统计学意义(P<0.05)。【结论】中药复方肠激灵能缓解IBS-D患者症状,提高患者生存质量,其近期疗效和远期疗效均优于西药对照组。     

Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial

Context.— The serotonin reuptake inhibitors are the treatment of choice for patients with obsessive-compulsive disorder; however, empirical support for this assertion has been weaker for children and adolescents than for adults. Objective.— To evaluate the safety and efficacy of the selective serotonin reuptake inhibitor sertraline hydrochloride in children and adolescents with obsessive-compulsive disorder. Design.— Randomized, double-blind, placebo-controlled trial. Patients.— One hundred eighty-seven patients: 107 children aged 6 to 12 years and 80 adolescents aged 13 to 17 years randomized to receive either sertraline (53 children, 39 adolescents) or placebo (54 children, 41 adolescents). Setting.— Twelve US academic and community clinics with experience conducting randomized controlled trials. Intervention.— Sertraline hydrochloride was titrated to a maximum of 200 mg/d during the first 4 weeks of double-blind therapy, after which patients continued to receive this dosage of medication for 8 more weeks. Control patients received placebo. Main Outcome Measures.— The Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), the National Institute of Mental Health Global Obsessive Compulsive Scale (NIMH GOCS), and the NIMH Clinical Global Impressions of Severity of Illness (CGI-S) and Improvement (CGI-I) rating scales. Results.— In intent-to-treat analyses, patients treated with sertraline showed significantly greater improvement than did placebo-treated patients on the CY-BOCS (adjusted mean, -6.8 vs -3.4, respectively; P = .005), the NIMH GOCS (-2.2 vs -1.3, respectively; P = .02), and the CGI-I (2.7 vs 3.3, respectively; P = .002) scales. Significant differences in efficacy between sertraline and placebo emerged at week 3 and persisted for the duration of the study. Based on CGI-I ratings at end point, 42% of patients receiving sertraline and 26% of patients receiving placebo were very much or much improved. Neither age nor sex predicted response to treatment. The incidence of insomnia, nausea, agitation, and tremor were significantly greater in patients receiving sertraline; 12 (13%) of 92 sertraline-treated patients and 3 (3.2%) of 95 placebo-treated patients discontinued prematurely because of adverse medical events (P = .02). No clinically meaningful abnormalities were apparent on vital sign determinations, laboratory findings, or electrocardiographic measurements. Conclusion.— Sertraline appears to be a safe and effective short-term treatment for children and adolescents with obsessive-compulsive disorder.      

Syndrome Pattern and Its Application in Parallel Randomized Controlled Trials

Syndrome pattern (SP) is a core concept of Chinese medicine (CM) and is used to diagnose and treat patients based on an overall analysis of symptoms and signs. This study aimed to systematically review randomized controlled trials (RCTs) using the SP concept and to demonstrate how the SP concept could be applied to the study design of parallel RCTs, considering a gold standard of clinical research. After conducting a brief systematic review by way of a PubMed search, we analyzed how the SP concept was applied to the design of RCT in a CM herbal medicine trial. We then formulated possible research questions, applied the SP concept to answer the research questions, and suggested possible RCT designs to be used for conducting future trials. Fourteen RCTs were included in our systematic review, and three key points of the SP concept were formulated for the design of parallel RCTs: the time point of SP diagnosis between before and after randomization; the relationship between the international classification of diseases (ICD) and SP for the inclusion of target population; and the proper diagnostic method of SP. In this study, we formulated three possible research questions and then suggested perspectives for five possible RCT models arrived at using SP concepts. Future trials applying SP concept to RCTs should overcome the shortcomings of past SP trials, moving CM forward from experience-based to evidence-based medicine.     

挑刺按摩配合中药调理治疗寻常痤疮疗效观察

目的观察挑刺清疮和中药按摩配合中药调理治疗寻常痤疮临床疗效。方法 215例寻常痤疮随机分两组,治疗组(117例)挑刺清疮和中药按摩配合中药调理;对照组(98例)中药调理。结果经8周治疗两组均有效,治疗组显效率明显优于对照组。结论挑刺清疮和中药按摩配合中药调理治疗寻常痤疮见效快,疗效显著。     

一清胶囊内服联合过氧化苯甲酰凝胶外涂治疗肺胃蕴热证痤疮的临床研究

目的:探讨一清胶囊内服联合过氧化苯甲酰凝胶外涂治疗肺胃蕴热证痤疮的临床效果。方法:将我院收治的肺胃蕴热证痤疮患者142例随机分为对照组和治疗组患者各71例。对照组患者给予过氧化苯甲酰凝胶外用,治疗组患者则加用一清胶囊内服,连用1个月。通过观察症状变化评价有效率,评估治疗前后皮损的改善情况,监测治疗前后血清睾酮水平变化。结果:治疗组患者的痤疮症状改善显著优于对照组患者,其有效率91.5%显著高于对照组77.5%,皮损改善明显优于对照组患者,皮损数目、皮损颜色、皮损痒痛评分显著低于治疗前及对照组患者,睾酮水平降低显著明显于对照组患者,差异具有统计学意义(P0.05)。结论:一清胶囊内服联合过氧化苯甲酰凝胶外涂治疗肺胃蕴热证痤疮疗效确切,利于改善痤疮患者的皮损程度,其机制与降低睾酮水平存在一定的相关性,值得临床深入探究。     

Reyanning Mixture on Asymptomatic or Mild SARS-CoV-2 Infection in Children and Adolescents:A Randomized Controlled Trial

Objective: To assess the effect and safety of Reyanning Mixture(RYN) in treating asymptomatic or mild severe acute respiratory syndrome coronavirus 2(SARS-Co V-2) infection in children and adolescents. Methods: This is a prospective, open-label, randomized control ed trial. Patients aged 1–17 years and diagnosed with asymptomatic or mild coronavirus disease-2019(COVID-19) were assigned to an intervention group(RYN plus standard care) and a control group(standard care) according to a randomizatio...     

内外同治治疗支气管哮喘发作期的随机对照试验研究

目的 评价清肺平喘颗粒联合固本清肺贴膏治疗支气管哮喘发作期(热哮证)的疗效与安全性.方法 将120例支气管哮喘发作期(热哮证)患者随机分为试验组和对照组,分别接受清肺平喘颗粒联合固本清肺贴膏与茶碱缓释片联合布地奈德粉吸入剂治疗,观察治疗前后中医症状积分、病情严重程度分级、哮喘控制测试表(ACT)及外周血嗜酸性粒细胞(EOS)计数等指标.结果 ①疾病疗效:清肺平喘颗粒联合固本清肺贴膏组(简称试验组)显效率为78.18％,总有效率为92.73％,茶碱缓释片联合布地奈德粉吸入剂(简称对照组)显效率为80.39％,总有效率为90.20％,2组间比较差异无统计学意义(P＞0.05).②中医证候疗效:试验组显效率为63.63％,总有效率为92.73％,对照组显效率为52.94％,总有效率为88.24％,2组间比较差异无统计学意义(P＞0.05).③病情严重程度分级及控制情况2组无明显差异(P＞0.05).④对外周血嗜酸性粒细胞(EOS)计数的影响2组无明显差异(P＞0.05).结论 清肺平喘颗粒联合固本清肺贴膏与茶碱缓释片联合布地奈德粉吸入剂疗效基本相当,未发现明显不良反应,为临床用药提供了新的选择.     

针刀松解法治疗第三腰椎横突综合征的多中心随机对照临床研究

目的:评价针刀松解法治疗第三腰椎横突综合征的临床疗效。方法:180例第三腰椎横突综合征患者随机分为针刀组和电针组,每组各90例,分别给予针刀松解法和电针疗法干预,共3周。采用JOA下腰痛评分表评价两组治疗前、治治疗后及治治疗后6月随访时的疗效。结果:两组治治疗后和随访时下腰痛、腿痛或麻木感、步态、腿抬高和加强试验、感觉障碍和运动障碍等评分均较治疗前明显增高,组间比较治治疗后和随访时评分与治疗前评分差值,针刀组下腰痛、腿痛或麻木感、步态、直腿抬高和加强试验的治疗后评分差值和随访评分差值均高于电针组,JOA评分等级分布优于电针组。结论:针刀松解法对治疗第三腰椎横突综合征有很好的近期疗效和远期疗效,在减轻疼痛症状和改善下肢功能方面优于电针疗法。     

Multicenter and Randomized Controlled Clinical Trial of Acupotomy Therapy in Treatment of Third Lumbar Transverse Process Syndrome

目的:评价针刀松解法治疗第三腰椎横突综合征的临床疗效.方法:180例第三腰椎横突综合征患者随机分为针刀组和电针组,每组各90例,分别给予针刀松解法和电针疗法干预,共3周.采用JOA下腰痛评分表评价两组治疗前、治治疗后及治治疗后6月随访时的疗效.结果:两组治治疗后和随访时下腰痛、腿痛或麻木感、步态、腿抬高和加强试验、感觉障碍和运动障碍等评分均较治疗前明显增高,组间比较治治疗后和随访时评分与治疗前评分差值,针刀组下腰痛、腿痛或麻木感、步态、直腿抬高和加强试验的治疗后评分差值和随访评分差值均高于电针组,JOA评分等级分布优于电针组.结论:针刀松解法对治疗第三腰椎横突综合征有很好的近期疗效和远期疗效,在减轻疼痛症状和改善下肢功能方面优于电针疗法.